MA45493A - Inhibiteurs d'entrée de hcmv. - Google Patents

Inhibiteurs d'entrée de hcmv.

Info

Publication number
MA45493A
MA45493A MA045493A MA45493A MA45493A MA 45493 A MA45493 A MA 45493A MA 045493 A MA045493 A MA 045493A MA 45493 A MA45493 A MA 45493A MA 45493 A MA45493 A MA 45493A
Authority
MA
Morocco
Prior art keywords
hcmc
entry inhibitors
inhibitors
entry
hcmc entry
Prior art date
Application number
MA045493A
Other languages
English (en)
Inventor
Barbara Adler
Sampaio Kerstin Laib
Christian Sinzger
Cora Stegmann
Original Assignee
Aicuris Anti Infective Cures Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Anti Infective Cures Gmbh filed Critical Aicuris Anti Infective Cures Gmbh
Publication of MA45493A publication Critical patent/MA45493A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA045493A 2016-06-27 2017-06-27 Inhibiteurs d'entrée de hcmv. MA45493A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16176520 2016-06-27

Publications (1)

Publication Number Publication Date
MA45493A true MA45493A (fr) 2019-05-01

Family

ID=56289338

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045493A MA45493A (fr) 2016-06-27 2017-06-27 Inhibiteurs d'entrée de hcmv.

Country Status (6)

Country Link
US (2) US11390661B2 (fr)
EP (1) EP3474887A1 (fr)
AR (1) AR108890A1 (fr)
CA (1) CA3028859A1 (fr)
MA (1) MA45493A (fr)
WO (1) WO2018002081A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
EP4031164A4 (fr) * 2019-09-17 2023-10-25 The Board Of Trustees Of The University Of Illinois Récepteurs modifiés pour le cytomégalovirus humain et leurs utilisations
WO2022013304A1 (fr) 2020-07-14 2022-01-20 Aicuris Gmbh & Co. Kg POLYPEPTIDES PDGFRα EN TANT QUE RÉCEPTEURS LEURRES VIRAUX
WO2022178415A1 (fr) * 2021-02-22 2022-08-25 Genentech, Inc. Procédés de modulation d'interactions de surface de cellule hôte avec des herpèsvirus

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
JP2001500015A (ja) 1996-09-06 2001-01-09 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｔ７ポリメラーゼを利用する組換えアデノ随伴ウイルスの誘導可能な製造方法
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6667173B2 (en) * 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
BR0212256A (pt) 2001-08-30 2004-08-31 Biorexis Pharmaceutical Corp Proteìnas de fusão de transferrina modificadas
DK2311432T3 (en) 2002-06-07 2015-02-02 Dyax Corp Modified Kunitz domain polypeptides and their use in reducing ischemia or the onset of a systemic inflammatory response associated with a surgical procedure
WO2005016966A2 (fr) * 2003-05-16 2005-02-24 Receptor Biologix, Inc. Proteines hybrides a intron et procede d'identification et d'utilisation de celles-ci
WO2005040229A2 (fr) 2003-10-24 2005-05-06 Avidia, Inc. Multimeres et monomeres comprenant des domaines de recepteur de lipoproteines de basse densite de classe a et egf
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
CA2560046A1 (fr) * 2004-03-16 2005-09-22 Dnavec Research Inc. Procede d'inhibition de la proliferation d'une tumeur
WO2006032436A2 (fr) 2004-09-21 2006-03-30 Nascacell Technologies Ag. Utilisation de microproteines en tant qu'inhibiteurs d'une tryptase
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
KR101246504B1 (ko) 2005-06-17 2013-03-26 임클론 엘엘씨 항－ＰＤＧＦＲα 항체
WO2009021150A2 (fr) * 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
ATE527353T1 (de) 2007-12-19 2011-10-15 Affibody Ab Pdgf-bindendes polypeptid aus protein a
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
BR112012004314A2 (pt) 2009-08-27 2016-11-29 Covagen Ag compostos de ligação a il-17 e usos medicinais desses compostos
EP2493911B1 (fr) 2009-10-30 2017-10-18 The Administrators of The Tulane Educational Fund Compositions peptidiques et procédés d'inhibition d'une infection par un virus de l'herpès
KR101436222B1 (ko) 2009-12-14 2014-09-01 쉴 프로테인즈 게엠베하 리간드 결합능력을 가진 헤테로-다량체 변형 유비퀴틴 단백질을 확인하는 방법
AU2011263786B2 (en) 2010-06-08 2014-11-13 Astrazeneca Ab Tear lipocalin muteins binding IL-4 R alpha
MX2014012843A (es) * 2012-04-24 2017-01-23 Thrombogenics Nv Anticuerpos anti-pdgf-c.

Also Published As

Publication number Publication date
US11390661B2 (en) 2022-07-19
US20210380664A1 (en) 2021-12-09
CA3028859A1 (fr) 2018-01-04
WO2018002081A1 (fr) 2018-01-04
US20190161532A1 (en) 2019-05-30
EP3474887A1 (fr) 2019-05-01
AR108890A1 (es) 2018-10-10

Similar Documents

Publication Publication Date Title
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
EP3541932A4 (fr) Inhibiteurs de crispr-cas9
EP3801503A4 (fr) Inhibiteurs de sarm1
EP3430731A4 (fr) Architecture d'iugw
EP3710547A4 (fr) Revêtements thermoscellables
EP3375323A4 (fr) Dispositif de formation de revêtement
MA52813A (fr) Inhibiteurs de sarm1
FR3059894B1 (fr) Pare-visage
MA52809A (fr) Inhibiteurs de sarm1
EP3824778A4 (fr) Pomme de douche
EP3817736A4 (fr) Inhibiteurs de pikfyve
DK3737403T5 (da) Modificerede adenovira
MA49006A (fr) Inhibiteurs d'ip6k
IL262701A (en) Enhancer of zeste homolog 2 inhibitors
EP3710548A4 (fr) Revêtements thermoscellables
MA51611A (fr) Inhibiteurs de pi4kiiibêta
EP3431808A4 (fr) Butée d'arrêt
EP3683214A4 (fr) Inhibiteur de brd4
DE102018108987A8 (de) Glättwerkzeug
PL3507018T3 (pl) Hydrocyklon
DK3599479T3 (da) Projektildetektering
ES1225190Y (es) Conjunto de ducha
PL3461561T3 (pl) Urządzenie odkamieniające